Please select the eligibility criteria that correspond to the clinical trial below.
Title: Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)
Brief Summary: The purpose of this study is to compare 5-year mortality rates in diabetic individuals with multivessel coronary artery disease (CAD) who undergo either coronary artery bypass grafting (CABG) surgery or percutaneous coronary stenting.


Options:
A: Inclusion Criteria:

* Type 2 diabetes
* eGFR \> 60 mL/min/1.73 mq (for the patients without renal failure)
* eGFR 10-60 mL/min/1.73 mq (for the patients with renal failure)

Exclusion Criteria:

* Type 1 diabetes
* Hypersensitivity to Linagliptin or excipients
* Intolerance to other DPP-4 inhibitors
* Terminal renal failure (eGFR \< 10 mL/min/1.73 mq)
* Use of GLP-1 analogs or other DPP-4 inhibitors
* Recent (within 1 month) trauma or surgery or acute diseases
* Any acute or chronic inflammatory condition
* Immunosuppression or organ transplantation
* Pregnancy or lactation
* Inability to provide informed consent.
B: Inclusion criteria

* History T2 DM
* Severe Renal Impairment

Exclusion criteria

* Glucose ≥ 270 mg/dL (≥15 mmol/L)
* Patients undergoing any method of dialysis
* Treatment with therapy other than sulfonylureas, TZDs ,insulin, and metiglinides
C: Inclusion Criteria: - Type 2 diabetes - Age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age min. 60 years at screening and other specified risk factors of cardiovascular disease - HbA1c: 7.0% or above - Anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (OADs) or treated with human NPH insulin or long-acting insulin analogue or premixed insulin, alone or in combination with OAD(s) Exclusion Criteria: - Type 1 diabetes - Use of a glucagon-like peptide-1 (GLP-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening (trial start) - Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigator's discretion
D: Inclusion Criteria:

* Diabetes mellitus (Type 1 or Type 2), defined according to the American Diabetes Association as either:

  1. presence of classic symptoms of diabetes mellitus with unequivocal elevation of plasma glucose (2-hour post-prandial or random of greater than 200 mg/dL (11mmol/L) or
  2. fasting plasma glucose elevation on more than one occasion of at least 126 mg/dL (7mmol/L)
* Currently undergoing pharmacological or non-pharmacological treatment for diabetes
* Angiographically confirmed multivessel CAD \[critical (greater than or equal to 70%) lesions in at least two major epicardial vessels and in at least two separate coronary artery territories (LAD, LCX, RCA)\] amenable to either PCI or CABG
* Angiographic characteristics amendable to both PCI/DES and CABG
* Indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia

Exclusion Criteria:

* Severe congestive heart failure (class III or IV according to New York Heart Association \[NYHA\] or pulmonary edema)
* Prior CABG surgery
* Prior valve surgery
* Prior PCI with stent implantation within 6 months of study entry
* Stroke within 6 months of study entry; if stroke occurred more than 6 months prior to study entry, must have significant residual neurologic involvement, as reflected in a Rankin Score of greater than 1
* Prior history of significant bleeding (within 6 months of study entry) that may occur during CABG or PCI/DES related anticoagulation
* In-stent restenosis of a target vessel
* Two or more chronic total occlusions in major coronary territories
* Left main stenosis (at least 50% diameter stenosis)
* Acute ST-elevation MI (Q-wave) within 72 hours of study entry requiring revascularization
* Abnormal creatine kinase level (greater than twice the normal limit); or abnormal CK-MB level at study entry
* Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g., valve repair/replacement, aneurysmectomy, carotid endarterectomy, or carotid stent)
* Cannot undergo either CABG or PCI/DES because of a coexisting medical condition
* Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis
* Intolerance to aspirin or both clopidogrel and ticlopidine
* Dementia with a score of less than 20 on the Mini Mental Status Examination (MMSE)
* Extra-cardiac illness that is expected to limit survival to less than 5 years (e.g., oxygen-dependent chronic obstructive pulmonary disease, active hepatitis, significant hepatic failure, or severe kidney disease)
* Pregnant
* Currently enrolled in another clinical trial
* Unable to attend required follow-up visits

Answer: D